Laura Dattaro

@ldattaro.bsky.social

Freelance journalist, covering science, health, and policy. Occasionally I write something fun. Comms/admin for @sciencewriting.bsky.social. Lauradattaro.com | LDattaro.73 on Signal

Senate easily advances stopgap funding deal past first hurdle www.politico.com/live-updates... "includes language to bar the Trump administration from putting into action a plan to make political appointees in charge of approving grants, a prohibition that would last for the length of the stopgap"

Senate easily advances stopgap funding deal past first hurdle

The 89-4 vote indicates strong bipartisan interest in avoiding another Oct. 1 shutdown.

politico.com

Wow, Senate seems to be really considering blocking the OMB rule. Collins specifically mentions the hundreds of thousands of negative comments the rule got—nearly half a million, per the federal register. (Which, I've been meaning to find out, is this a record?) www.politico.com/live-updates...

Top senators consider blocking Trump’s grant shakeup in spending stopgap

It’s now “up to leadership” whether to head off the controversial changes, Sen. Susan Collins said.

politico.com

🚨 WE HAVE A DEAL! After three years, in a major step forward for our members, we have ratified our first contract with @propublica.org’s management. We deeply appreciate everyone who supported us along the way. Here are some of our big wins👇

A graphic poster reads "We have a deal! The ProPublica Guild has reached a deal with ProPublica's management on our first contract and has voted to ratify it. Swipe for the highlights [pointing emoji].

I wrote about a new policy on research that manipulates pathogens—potentially high risk but crucial for protecting us from deadly diseases, sources told me. Of course, the context around COVID & the Fauci hearing can't be ignored. For @cenmag.bsky.social cen.acs.org/policy/dgof-...

White House bans agencies from funding some research on pathogens

The new policy prohibits federal support of ‘gain of function’ research of concern, in which scientists manipulate pathogens and other biological agents in order to better understand them

cen.acs.org

FASEB Launches “Defend Science Research,” a Tool for Submitting Comments on the OMB Proposed Rule www.faseb.org/science-poli... "...an online tool that helps medical researchers, scientific societies develop, and others develop personalized comments on the OMB proposed rule."

Defend Research

We advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to our societies and their members.

faseb.org

I’m so sad to share that yesterday was my last day at Scientific American. It was an honor to work alongside my incredible colleagues and to speak with researchers across the sciences. If you’re looking to hire staff or freelance, please consider me and my other laid off coworkers (🧵)

Enjoyed reading this. How EPA works is a puzzle to me, but this helped. Bill Foster is a treasure - he represents the district my company is in. When we write grant briefs "for members of congress" we keep in mind they mean a typical member and not him!

Vicki Schneps-Yunis and Josh Schneps have built a NYC-metro local news empire on the backs of journalists making $40,000 a year. Today, those journalists announced they're forming a union and demanding fair salaries. hellgatenyc.com/schneps-edit...

The Journalists at NYC's Largest Local News Print Chain Are Unionizing

Reporters at Schneps Media, which includes amNew York, Queens Courier, and the Brooklyn Paper, say they can’t afford to live on their salaries.

hellgatenyc.com

I'm not sure I've ever gotten a more enthusiastic comment on a study I'm covering: "I’m always cautious about how I describe advances in cancer treatment because I don’t want to prematurely raise hope in patients. In this case here, this is huge." www.the-scientist.com/daraxonrasib...

Daraxonrasib Drug Doubles Pancreatic Cancer Survival Rate in Phase 3 Trial | The Scientist

An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic and other cancers.

the-scientist.com